Skip to main content

SABCS 2020 - HER2+

The potential role of the combination of pertuzumab, hormone therapy, plus an aromatase inhibitor as first-line treatment for HER2-positive metastatic or locally advanced breast cancer is further supported by the final analysis of the PERTAIN trial. Read More ›

Elderly patients with HER2-positive advanced breast cancer demonstrated shorter chemotherapy durations, poorer overall survival, and increased rates of adverse events, emphasizing the need for prospective studies to improve outcomes. Read More ›

Page 2 of 2